Clinical Trial Detail

NCT ID NCT02259725
Title Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors University of Southern California
Indications

neuroendocrine tumor

Therapies

Regorafenib

Age Groups: adult

No variant requirements are available.